Sanofi Ventures
Corporate VCSeedβLate Stage Β· 12 people tracked
Investment thesis
Sanofi Ventures invests in top-tier biotech and digital health companies focused on helping patients and transforming medical practice. The fund targets transformational science and technology in early-stage companies that are too early to partner with or acquire directly by Sanofi. Investment activities include leading financings, serving on boards, and collaborating with portfolio companies to drive long-term value creation. The fund explicitly focuses on innovations in biotech and digital health with strategic relevance to Sanofi's core therapeutic areas.
Source: firm website, verified Jul 21, 2026.
Team Β· 12 people
from the firm's websiteJoined Sanofi Ventures in 2020 as Partner leading Digital Health and Artificial Intelligence investments. Brings over 20 years of healthtech experience including roles as founding member of Johnson & Johnson Innovation and Global Head of Digital Innovation. Co-founded Ultra Light Startups, a venture pitch accelerator, and served in emerging technology roles at Novartis.
Joined Sanofi Ventures in 2014 with early-stage biotech investing and transaction experience. Previously held positions including Director of Corporate Development at Translate Bio, Associate at Atlas Venture, Flagship Ventures Entrepreneurial Fellow, and analyst at an investment banking firm focused on life sciences.
Joined Sanofi Ventures in 2018 with background in early-stage biotech investing and drug development. Previously served as Investment Director at Ysios Capital and held roles in the pharmaceutical and research sectors, including positions at Janssen-Cilag and companies such as Spirogen and Medivir.
Joined Sanofi Ventures in 2022 with background in early-stage biotech investing and company building. Previously served as Principal at Omega Funds where she incubated and invested in companies including Scorpion Therapeutics. Earlier career included roles at Polaris Partners with board service on multiple public and private biotech companies.
Joined Sanofi Ventures in 2017 with background in life science and healthcare consulting. Previously spent three years at L.E.K. Consulting focused on corporate strategy, due diligence, and commercial planning in pharmaceutical and biotech sectors. Completed postdoctoral fellowship at Harvard University.
Joined Sanofi Ventures in 2021 with background in biotech investing and business development. Previously worked with the External Innovation team at Vertex Pharmaceuticals and at RA Capital, a crossover investment fund. Holds a Ph.D. in Neuroscience from MIT.
Joined Sanofi Ventures in May 2023 after 19 years in various departments at Sanofi, including Digital Vaccines, business development, and global digital initiatives.
Joined Sanofi Ventures in 2026 with background in biopharma investing. Previously evaluated both private and public biotech companies at Bain Capital Life Sciences. Holds a Ph.D. in biological and biomedical sciences from Harvard University.
Joined Sanofi Ventures in 2024 with background in early-stage biotech investing, technology transfer, and biotech management. Spent three years at AdBio Partners as part of the team establishing the Barcelona office. Earlier career included operational roles at emerging gene and cell therapy companies and technology transfer offices.
Joined Sanofi Ventures in 2026 with background in healthcare services, digital health, and medtech investing. Previously spent four years at RA Capital Management on the Health Technology and Services team, investing across both public equities and venture. Holds a Ph.D. from MIT.
Joined Sanofi Ventures in 2024 with background in biopharma investing. Previously worked as Analyst at Jeito Capital focused on oncology, cardiology, and neuroscience. Earlier experience includes research roles at Smart Immune and Institut Imagine, a leading European center for genetic disease research.
Joined Sanofi Ventures in 2025 with broad background across the pharma value chain. Worked at Sanofi since 2020 as legal partner for strategic investments and licensing transactions. Prior experience includes in-house counsel at Fresenius Medical Care and transaction work at law firm Foley Hoag LLP.
What they invest in
from 23 of 111 portfolio companiesBiotech Γ17Medical Devices Γ12Healthtech Γ10Digital Health Γ7AI & Machine Learning Γ6Deep Tech Γ5Data & Infrastructure Γ1Defense Tech Γ1
HQs:United StatesΓ3SwitzerlandΓ1SpainΓ1
Investments Β· showing 60 of 111
founders shown can be your intro pathGranite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options. The company is based in Basel, Switzerland, with a pipeline including Minokitug for autoimmune inflammation and GRT-002 for allergy and itch conditions.
BiotechMedical DevicesBasel, CH
Patrick Loustau(President and Chief Executive Officer)
Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization. The company serves patients with immunological disorders and rare genetic conditions.
BiotechDeep TechHealthtech
Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)
SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes. The company is currently in clinical stages, with its lead program targeting Stargardt Disease.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Vila-PerellΓ³(CEO)Dr. Frutos(Co-founder)
Atalanta is a mathematical AI company that provides software verification and formal methods capabilities to ensure provably correct decision-making in complex systems for high-stakes missions in energy, space, and defense sectors.
AI & Machine LearningDeep TechDefense Tech
Attovia develops precision biologics using its ATTOBODY platform for patients with immune-mediated diseases. The company creates novel complex biologic medicines through modular protein design.
BiotechDigital Health
Avilar develops protein degrader drugs targeting extracellular and membrane-bound proteins, using a novel class called ATACs that harness endolysosomal degradation machinery. The company focuses on treating serious human diseases where currently undrugged extracellular proteins play a pathogenic role.
AI & Machine LearningBiotechMedical Devices
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. The therapies use modified blood stem cells to restore function of affected genes and offer potential cures rather than symptom management.
BiotechLongevityMedical Devices
David Meek(Chief Executive Officer)Brian Riley(President & Chief Technical Officer)Joanne Lager(Chief Medical Officer)Wendy DiCicco(Chief Financial Officer)
Evidation collects and analyzes real-world health data from millions of community members to enable clinical research and health programs across various medical conditions. The platform partners with healthcare organizations, biomedical firms, government agencies, and nonprofits to drive discoveries and inform healthcare decision-making using everyday health data.
BiotechData & InfrastructureDigital HealthHealthtech
<UNKNOWN>
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options. The company focuses on addressing unmet medical needs in the rare disease space.
Biotech
Steven Axon(Chief Executive Officer)Hicham Alaoui(Chief Scientific Officer)Rose Marino(Chief Medical Officer)Peter McWilliams(Chief Business Officer)
Biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections using ionic liquid technology
Trial Library is an AI-native platform that integrates clinical trials into routine healthcare by connecting patients, providers, payers, and pharmaceutical sponsors. The platform accelerates patient enrollment and trial access across health systems, clinics, and specialty practices.
AI & Machine LearningDigital HealthHealthtech
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins. The company focuses on advancing small molecule therapies designed to address critical health problems across multiple disease areas.
BiotechDeep TechHealthtech
MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients, including oncology, hematology, and autoimmune applications. The company uses platform technologies such as antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers.
BiotechMedical Devices
Medisafe is a medication engagement platform that helps pharmaceutical companies connect with patients beyond the prescription and improve treatment adherence. The platform uses personalized, intelligent engagement to support patients with complex therapies across multiple therapeutic areas.
Digital HealthHealthtechMedical Devices
Privately-held biotech company developing biologic therapies for retinal diseases
Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach. The company targets therapeutics to improve treatment efficacy beyond current standards in immunology and fibrotic conditions.
AI & Machine LearningMedical Devices
Frequently asked questions
- What stage does Sanofi Ventures invest at?
- Sanofi Ventures invests at the Seed, Series A, Series B, Growth, Late Stage stages.
- What sectors does Sanofi Ventures focus on?
- Sanofi Ventures focuses on AI & Machine Learning, Biotech, Digital Health.
- Does Sanofi Ventures lead rounds?
- Yes, Sanofi Ventures leads investment rounds.
Images
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
USVP is a venture capital firm with over 40 years of history across four generations of technology investing. The firm has deployed $4.7B across 542 companies, generating 97 IPOs, and combines 150 years of combined operating experience with deep expertise in enterprise software, security, consumer technology, and healthcare.
A venture capital firm that supports founders developing transformative solutions across interconnected systems, with a particular focus on leveraging artificial intelligence and related technologies to advance health and human flourishing.